World-first clinical trial to test promising new approach to target triple-negative breast cancer
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
World-first clinical trial to test promising new approach to target triple-negative breast cancer
-
Narrated by:
-
By:
About this listen
Metastatic triple-negative breast cancer has limited treatment options and is commonly diagnosed in younger women, aged under 40. But a promising combination therapy could offer a new approach to target this highly aggressive and treatment-resistant type of breast cancer. QIMR Berghofer Professor Sudha Rao and Kazia Therapeutics CEO Dr John Friend share the incredible story that led to their collaboration, and a world-first clinical trial.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.